Martine B W Prinsen Selected Research

NTRC 0066-0

11/2017

TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martine B W Prinsen Research Topics

Disease

8	Neoplasms (Cancer) 01/2020 - 01/2014
2	Melanoma (Melanoma, Malignant) 01/2020 - 01/2015
1	Triple Negative Breast Neoplasms 01/2017
1	Breast Neoplasms (Breast Cancer) 01/2015
1	Retinoblastoma (Glioblastoma, Retinal) 01/2015

Drug/Important Bio-Agent (IBA)

4	Pharmaceutical PreparationsIBA 01/2019 - 01/2014
2	Phosphotransferases (Kinase)IBA 01/2019 - 01/2014
2	CateninsIBA 11/2017 - 01/2015
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2015 - 01/2014
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2020
1	Tryptophan (L-Tryptophan)FDA Link 01/2020
1	KynurenineIBA 01/2020
1	ibrutinibIBA 01/2019
1	NTRC 0066-0IBA 11/2017
1	Biomarkers (Surrogate Marker)IBA 11/2017
1	Protein Kinases (Protein Kinase)IBA 01/2017
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2017
1	Threonine (L-Threonine)FDA Link 01/2017
1	Antineoplastic Agents (Antineoplastics)IBA 12/2016
1	Investigational DrugsIBA 12/2016
1	Cyclin DIBA 01/2015
1	palbociclibIBA 01/2015
1	Drug CombinationsIBA 01/2015
1	EnzymesIBA 01/2014
1	trametinibIBA 01/2014

Therapy/Procedure

3	Therapeutics 11/2017 - 01/2015
1	Immunotherapy 01/2020